Curis, Inc. · NASDAQ:CRIS
Curis — Technical Presentation (December 2022)
6 slides from Curis's technical presentation, Dec 12, 2022
Slide 1: TakeAim Leukemia Update
TakeAim Leukemia Update December 12, 2022
Slide 2: Cautionary Note Regarding Forward Looking Statements
Cautionary Note Regarding Forward Looking Statements This presentation contains certain forward-looking statements about Curis, Inc. (“we,” “us,” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “expect(s),” “believe(s),” “will,”
Slide 3: Emavusertib Monotherapy Activity Reinforced in Updated Data
Emavusertib Monotherapy Activity Reinforced in Updated Data New data roughly doubles the targeted patient population (FLT3 or Spliceosome mutation) Monotherapy Patients, Grouped by Mutation Status Consistent, deep anticancer activity with a single agent 24 patients 34 patients with targeted mutation
Slide 4: Emavusertib Monotherapy Activity Reinforced in Updated Data
Emavusertib Monotherapy Activity Reinforced in Updated Data New data show consistent, deep anticancer activity with a single agent with targeted mutations Monotherapy In Patients with FLT3 Mutation In this population, IRAK4 is a key driver of resistance to FLT3 inhibition; updated data show multiple
Slide 5: Initial Data Show Emavusertib is Highly Active in Combination
Initial Data Show Emavusertib is Highly Active in Combination Initial combination data in AML/MDS are consistent with data seen in NHL/CLL all comers Combination Combination in NHL/CLL Blocking both of the two pathways that drive overactivity of NFκB BTK-naïve BTK-experienced (BCR pathway and TLR pa
Slide 6: Emavusertib Induced Molecular Responses
Emavusertib Induced Molecular Responses Disease modifying activity in spliceosome-, FLT3- and dual-mutated disease HR-MDS Case 1 (mCR) Patient with hrMDS harboring U2AF1 mutation Demonstrates loss of not only the mutated splicing factor U2AF1, but also STAG2, DNMT3A and BCOR AML Case 1 (mCR) Patient